- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | BioAdaptives Inc.: BioAdaptives Announces Commercial Launch of MyndMed Following Successful Pilot Testing | 108 | GlobeNewswire (Europe) | LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed, a next-generation cognitive-support dietary supplement... ► Artikel lesen | |
| 20.08. | BioAdaptives Inc.: BioAdaptives' MyndMed Receives Full Clearance from TruShield, Meeting UFC and WADA Standards for Athlete Safety | 1 | GlobeNewswire (USA) | ||
| 14.08. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 24.06. | BioAdaptives Inc.: BioAdaptives Announces National Launch of Pawpa Regen | 3 | GlobeNewswire (USA) | ||
| 28.05. | BioAdaptives Inc.: BioAdaptives PawPa Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR Scale Improvements | 1 | GlobeNewswire (USA) | ||
| 13.05. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 13.03. | BioAdaptives Inc.: Zeranovia Weight Loss Product Shows Promising Results in Dosage Trial | 142 | GlobeNewswire (Europe) | LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia.... ► Artikel lesen | |
| 25.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia | 146 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia. The trial, approved... ► Artikel lesen | |
| 13.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions | 128 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a leading provider of innovative nutritional products, announces today a transformative shift in its product... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | 0,00 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | 0,00 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| VENTYX BIOSCIENCES | 8,560 | 0,00 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | 0,00 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data | ||
| PRIME MEDICINE | 4,950 | +13,79 % | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy | ||
| ARCUS BIOSCIENCES | 19,645 | -2,41 % | Arcus Biosciences stock falls after pricing $250 million public offering | ||
| MINERALYS THERAPEUTICS | 40,830 | -0,73 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
BIOADAPTIVES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.